Startups channel feed

Alen­tis nabs $181M to broad­en Claud­in's scope in AD­Cs

6 months ago
Financing

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

6 months ago
Deals

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

6 months ago
Financing

GSK snags Parkin­son's drug from Flag­ship start­up Vesal­ius

6 months ago
Deals
Pharma

Yorvipath’s ap­proval show­cas­es bio­phar­ma’s in­ter­est in rare en­docrine dis­or­der

6 months ago
R&D
In Focus

Stephen Squin­to's JPM life sci­ences team is rais­ing a new fund for lat­er-stage com­pa­nies

6 months ago
Financing

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

6 months ago
Deals
China

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

6 months ago
R&D
Pharma

Cere­bral to pay near­ly $3.7M over con­trolled sub­stance pre­scrib­ing prac­tices

6 months ago
Pharma
Health Tech

Why hos­pi­tals have been slow to adopt AI for med­ical care

6 months ago
AI
Health Tech

Q&A: Jade CEO talks about re­verse merg­er and IgAN drugs

6 months ago
Deals

Evom­mune rais­es $115M for I&I pipeline and pre­pares for Phase 2 re­sults

6 months ago
Financing

Ab­b­Vie adds to T cell en­gager mo­men­tum, with EvolveIm­mune pact start­ing at $65M

6 months ago
Deals
Pharma

An­oth­er Paragon off­shoot inks re­verse merg­er as Jade takes Aerovate’s place

6 months ago
Deals

Blue Earth Ther­a­peu­tics snags $76M for both al­pha and be­ta ra­dio­ther­a­pies

6 months ago
Financing

A start­up backed by No­bel win­ner David Bak­er takes an AI twist on an­ti­bod­ies

6 months ago
Financing
AI

Ax­o­nis snags $115M to test oral drugs for epilep­sy and neu­ro­path­ic pain

6 months ago
Financing

Cor­rect­ed: Gen­mab lines up T cell en­gager pact with Re­vi­tope

6 months ago
Deals
Pharma

Ab­b­Vie makes $1.4B ac­qui­si­tion of Alzheimer's biotech

6 months ago
Deals
Pharma

Synaf­fix, in­dus­try's ADC part­ner of choice, spins out a start­up pipeline

6 months ago
Financing

For­mer Seagen CEO David Ep­stein to lead new biotech with VEGF bi­func­tion­al an­ti­body

6 months ago
R&D

Fog­Phar­ma re­brands as Para­bilis Med­i­cines, as CEO Math­ai Mam­men high­lights next drugs

6 months ago
R&D

Telix's new ra­dio­phar­ma spin­out banks on one tri­al for suc­cess, CEO says

7 months ago
Manufacturing

Elu­ci­da On­col­o­gy, seek­ing foothold in AD­Cs, shut­ters due to 'lack of fund­ing'

7 months ago
People
First page Previous page 6789101112 Next page Last page
A service from the Financial Times